AR025754A1 - Secretasa en la enfermedad de alzheimer, sustratos de la app y sus usos - Google Patents

Secretasa en la enfermedad de alzheimer, sustratos de la app y sus usos

Info

Publication number
AR025754A1
AR025754A1 ARP000104987A ARP000104987A AR025754A1 AR 025754 A1 AR025754 A1 AR 025754A1 AR P000104987 A ARP000104987 A AR P000104987A AR P000104987 A ARP000104987 A AR P000104987A AR 025754 A1 AR025754 A1 AR 025754A1
Authority
AR
Argentina
Prior art keywords
app
secretase
alzheimer
disease
assays
Prior art date
Application number
ARP000104987A
Other languages
English (en)
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/416,901 external-priority patent/US6699671B1/en
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of AR025754A1 publication Critical patent/AR025754A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96472—Aspartic endopeptidases (3.4.23)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente proporciona la enzima y los procedimientos enzimáticos para escindir el sitio de escision de alfa-secretasa de la proteína precursora delamiloide (APP), y los correspondientes ácidos nucleicos, péptidos, vectores, células y aislados celulares, y ensayos. También se proporciona una enzima quecorta el sitio alfa-secretasa de APP. La invencion además proporciona una proteína APP modificada y sus correspondientes ácidos nucleicos, péptidos, vectores,células y aislados celulares, y ensayos que son especialmente utiles para identificar substancias potencialmente terapéuticas en el tratamiento o laprevencion de la enfermedad de Alzheimer.
ARP000104987A 1999-09-23 2000-09-22 Secretasa en la enfermedad de alzheimer, sustratos de la app y sus usos AR025754A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15549399P 1999-09-23 1999-09-23
US09/416,901 US6699671B1 (en) 1998-09-24 1999-10-13 Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US16923299P 1999-12-06 1999-12-06

Publications (1)

Publication Number Publication Date
AR025754A1 true AR025754A1 (es) 2002-12-11

Family

ID=34753605

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104987A AR025754A1 (es) 1999-09-23 2000-09-22 Secretasa en la enfermedad de alzheimer, sustratos de la app y sus usos

Country Status (12)

Country Link
EP (1) EP1224297B1 (es)
AR (1) AR025754A1 (es)
AT (1) ATE431419T1 (es)
AU (1) AU782312B2 (es)
CA (1) CA2397786A1 (es)
CO (1) CO5770112A1 (es)
DK (1) DK1224297T3 (es)
ES (1) ES2327312T3 (es)
PE (1) PE20010693A1 (es)
PT (1) PT1224297E (es)
TW (2) TWI294462B (es)
WO (1) WO2001023533A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456007B1 (en) 1998-12-31 2008-11-25 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
US7115410B1 (en) 1999-02-10 2006-10-03 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
AU4000900A (en) 1999-02-10 2000-08-29 Elan Pharmaceuticals, Inc. Beta-secretase enzyme compositions and methods
WO2000058479A1 (en) 1999-03-26 2000-10-05 Amgen Inc. Beta secretase genes and polypeptides
CN1379819A (zh) 1999-06-28 2002-11-13 俄克拉荷马州医学研究基金会 具有催化活性的重组memapsin蛋白酶及其应用方法
US7514408B1 (en) 1999-12-02 2009-04-07 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
WO2001070672A2 (en) 2000-03-23 2001-09-27 Elan Pharmaceuticals, Inc. Compounds and methods to treat alzheimer's disease
US6713276B2 (en) 2000-06-28 2004-03-30 Scios, Inc. Modulation of Aβ levels by β-secretase BACE2
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
EP1666452A2 (en) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
US7806980B2 (en) 2000-12-23 2010-10-05 Elan Pharmaceuticals, Inc. Method for crystallizing human beta secretase in complex with an inhibitor
US7601528B1 (en) 2000-12-23 2009-10-13 Elan Pharmaceuticals, Inc. Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in alzheimer's disease
US7217556B1 (en) 2000-12-23 2007-05-15 Pfizer Inc Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in Alzheimer's disease
US7524668B1 (en) 2001-05-10 2009-04-28 Elan Pharmaceuticals, Inc. Crystal of human beta secretase having monoclinic space group symmetry C2 and methods for crystallization thereof
US7384773B1 (en) 2001-05-10 2008-06-10 Pfizer Inc Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
US7144897B2 (en) 2001-06-01 2006-12-05 Elan Oharmaceuticals, Inc. Hydroxy alkyl amines
JP2004532894A (ja) 2001-06-13 2004-10-28 イーラン　ファーマスーティカルズ、インコーポレイテッド アルツハイマー病を治療するためのアミンジオール
BR0211118A (pt) 2001-07-10 2004-10-26 Elan Pharm Inc Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
JP2005505517A (ja) 2001-07-10 2005-02-24 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病を治療するためのアミンジオール
AU2002345247A1 (en) * 2001-07-26 2003-02-17 Astex Technology Ltd Crystal structure of beta-site app cleaving enzyme (bace) and use thereof
US7186539B1 (en) 2001-08-31 2007-03-06 Pharmacia & Upjohn Company Method for refolding enzymes
US7244755B2 (en) 2001-10-04 2007-07-17 Pharmacia & Upjohn Company Hydroxypropylamines
EP1448218A4 (en) 2001-10-23 2009-01-14 Oklahoma Med Res Found BETA SECRETASE INHIBITORS AND METHODS OF USE
US7045311B2 (en) 2001-10-25 2006-05-16 Monogram Biosciences, Inc. Whole cell assay systems for cell surface proteases
EA200400648A1 (ru) 2001-11-08 2005-04-28 Элан Фармасьютикалз, Инк. N, n'-замещенные производные 1,3-диамино-2-гидроксипропана
EP1572904B1 (en) 2002-02-21 2009-04-15 Pharmacia & Upjohn Company LLC Modified bace
AU2003303141A1 (en) 2002-04-30 2004-07-22 Elan Pharmaceuticals, Inc. Hydroxypropyl amides for the treatment of alzheimer's disease
US7442537B1 (en) 2002-05-10 2008-10-28 Elan Pharmaceuticals, Inc. Crystals of unliganded beta secretase and/or beta secretase-like proteins and the use thereof
JP2004000060A (ja) * 2002-05-31 2004-01-08 Otsuka Pharmaceut Co Ltd アミロイドβ産生に影響を与える化合物のスクリーニング方法
WO2004050609A1 (en) 2002-11-27 2004-06-17 Elan Pharmaceutical, Inc. Substituted ureas and carbamates
WO2004094384A2 (en) 2003-04-21 2004-11-04 Elan Pharmaceuticals, Inc. (hetero) arylamide 2-hydroxy-3-diaminoalkanes for use in the treatment of alzheimer’s disease
JP4739192B2 (ja) 2003-05-02 2011-08-03 イーラン ファーマスーティカルズ、インコーポレイテッド Ｂａｃｅのグリコシル化変異体
CA2558034A1 (en) 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
JP2008505930A (ja) 2004-07-09 2008-02-28 エラン ファーマシューティカルズ，インコーポレイテッド オキシム誘導体置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
AU2006208226A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
WO2007047305A1 (en) 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
WO2009007300A2 (en) 2007-07-06 2009-01-15 Boehringer Ingelheim International Gmbh Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
EP2281824A1 (en) 2009-08-07 2011-02-09 Noscira, S.A. Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
JP2013542973A (ja) 2010-11-22 2013-11-28 ノスシラ、ソシエダッド、アノニマ 神経変性疾患または神経変性状態を治療するためのビピリジンスルホンアミド誘導体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09178743A (ja) * 1995-12-27 1997-07-11 Oriental Yeast Co Ltd 可溶性ａｐｐの定量法
EP0848062A3 (en) * 1996-12-14 2000-07-05 Smithkline Beecham Corporation Aspartic protease ASP1
AU1726199A (en) * 1997-12-31 1999-07-19 Chiron Corporation Metastatic cancer regulated gene
PL205294B1 (pl) * 1998-09-24 2010-03-31 Upjohn Co Izolowany lub oczyszczony polipeptyd, oczyszczony lub izolowany polinukleotyd, wektor, wektor ekspresyjny, komórka gospodarza, sposób wytwarzania polipeptydu, sposoby identyfikowania czynnika obniżającego, modulującego lub hamującego aktywność, zastosowanie takiego czynnika, izolowany kwas nukleinowy, obejmujący go wektor i ich zastosowanie, sposoby zmniejszania komórkowego wytwarzania beta amyloidu i zastosowanie antysensownego reagenta

Also Published As

Publication number Publication date
ES2327312T3 (es) 2009-10-28
AU7607100A (en) 2001-04-30
TWI294462B (en) 2008-03-11
CA2397786A1 (en) 2001-04-05
PT1224297E (pt) 2009-08-17
TW200745552A (en) 2007-12-16
PE20010693A1 (es) 2001-06-24
EP1224297B1 (en) 2009-05-13
CO5770112A1 (es) 2007-06-29
ATE431419T1 (de) 2009-05-15
AU782312B2 (en) 2005-07-21
DK1224297T3 (da) 2009-09-07
WO2001023533A2 (en) 2001-04-05
EP1224297A2 (en) 2002-07-24
WO2001023533A3 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
AR025754A1 (es) Secretasa en la enfermedad de alzheimer, sustratos de la app y sus usos
ATE420185T1 (de) Alzheimersche krankheit sekretase
WO2001050829A3 (en) Alzheimer's disease secretase, app substrates therefor, and uses therefor
AU3649397A (en) Precise efficacy assay methods for active agents including chemotherapeutic agents
ATE485366T1 (de) Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau
EP2444810A3 (en) Proteases mutants with altered specificity and uses thereof
DE69621953T2 (de) Vehikel zum einbringen von nukleinsäuren in zellen
DE69734974D1 (de) Verfahren zur transformation dendritischer zellen und aktivierung von t zellen
NZ513923A (en) Methods for detecting membrane derived caspase activity and modulators thereof
ECSP003672A (es) Secretasa en la enfermedad de alzheimer, substratos de la app y sus usos
AU8398801A (en) Two coloured fluorimetric protease assay
Yamaguchi et al. Characterization of regucalcin effect on proteolytic activity in rat liver cytosol: relation to cysteinyl-proteases
BR0001906A (pt) Processo para a preparação fermentativa de l-aminoácidos usando bactérias corineformes
BRPI0509941A (pt) proteases e usos das mesmas
ES2160807T3 (es) Fragmento de adn que codifica la oxidasa de d-aminoacidos.
WO2002074921A3 (en) Methods for isolating proteins expressed by dendritic cells
DE60225587D1 (de) Protease assay zur kontrolle medikamentöser therapie
CY1110496T1 (el) Σεκρεταση νοσου alzheimer, υποστρωματα app αυτης, και χρησεις αυτης
BR0317780A (pt) Formulação na forma de supositório para a administração retal, método para o tratamento de hemorróidas, e uso de peptìdeos e proteìnas com ação trombolìtica para o tratamento de hemorróidas
AU4269401A (en) HCV NS2/3 fragments and uses thereof
HUP0002281A2 (hu) Eljárás sejtfelszíni fehérjék elleni vakcinák termelésére
WO2004022702A3 (en) Methods and reagents for identifying inhibitors of viral protease activity.
MX9706725A (es) Mezclas enzimaticas definidas, novedosas para obtener celulas y para tratamientos de heridas.
TH51992A (th) ซีครีเทสของโรคแอลซ์ไฮม์เมอร์ app สับสเตรทของมัน และการใช้งานของมัน

Legal Events

Date Code Title Description
FB Suspension of granting procedure